Rhythm Biosciences's total inventories for the quarter that ended in Dec. 2025 was €0.04 Mil. Rhythm Biosciences's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was €0.04 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Rhythm Biosciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was €0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Rhythm Biosciences's Days Inventory for the
six
months ended in Dec. 2025 was 80.57.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Rhythm Biosciences's Inventory Turnover for the quarter that ended in Dec. 2025 was 2.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rhythm Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 1.60.
Rhythm Biosciences (FRA:0RY) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Rhythm Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rhythm Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Rhythm Biosciences Total Inventories Related Terms
Rhythm Biosciences Total Inventories Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Rhythm Biosciences (FRA:0RY) has a Total Inventories of €0.04 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Rhythm Biosciences and its competitors.
Is Rhythm Biosciences' Total Inventories too high?
Rhythm Biosciences' current Total Inventories is €0.04 Mil. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Total Inventories compare to TMO and DHR?
Rhythm Biosciences' Total Inventories of €0.04 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Diagnostics & Research company?
A good Total Inventories depends on the Medical Diagnostics & Research industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Rhythm Biosciences and its competitors. Rhythm Biosciences's current Total Inventories is €0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Total Inventories of €0.04 Mil. The current Total Inventories is €0.04 Mil. Rhythm Biosciences' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Total Inventories is €0.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
